EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic.
COVID-19
chronic disease
human
neurology
practice guideline
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
25
06
2020
revised:
20
08
2020
accepted:
31
08
2020
pubmed:
16
10
2020
medline:
8
1
2021
entrez:
15
10
2020
Statut:
ppublish
Résumé
The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19. A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements. In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.
Sections du résumé
BACKGROUND AND PURPOSE
The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19.
METHODS
A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements.
RESULTS
In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy.
CONCLUSION
This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.
Identifiants
pubmed: 33058321
doi: 10.1111/ene.14521
pmc: PMC7675361
doi:
Types de publication
Guideline
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-14Informations de copyright
© 2020 The Authors. European Academy of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Neuro Oncol. 2020 May 05;:
pubmed: 32369601
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Neurosurg Anesthesiol. 2020 Jul;32(3):202-209
pubmed: 32301764
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):
pubmed: 32414755
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jul;393(7):1131-1135
pubmed: 32415494
J Neurosurg Anesthesiol. 2020 Jul;32(3):193-201
pubmed: 32282614
Stroke Vasc Neurol. 2020 Jun;5(2):146-151
pubmed: 32385132
Rev Neurol (Paris). 2020 Jun;176(6):507-515
pubmed: 32354651
Eur J Neurol. 2020 Sep;27(9):e31-e32
pubmed: 32323891
Neurol Sci. 2020 Jun;41(6):1345-1348
pubmed: 32363507
Lancet Neurol. 2020 Jun;19(6):482
pubmed: 32470415
Eur J Neurol. 2020 Sep;27(9):1727-1737
pubmed: 32558002
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Parkinsons Dis. 2020;10(3):903-910
pubmed: 32333552
J Neurol Sci. 2020 May 15;412:116803
pubmed: 32247193
Nat Rev Neurol. 2020 Jul;16(7):347-348
pubmed: 32444648
Eur J Neurol. 2020 Aug;27(8):1578-1587
pubmed: 32416028
Neurology. 2020 Jul 28;95(4):167-172
pubmed: 32414880
Stroke. 2020 Jun;51(6):1910-1912
pubmed: 32233972
Mult Scler Relat Disord. 2020 Aug;43:102174
pubmed: 32464584
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
J Neurointerv Surg. 2020 Jun;12(6):542-544
pubmed: 32303584
Eur J Neurol. 2020 Sep;27(9):1710-1711
pubmed: 32460417